SCTB14
Phase 3Small molecule
SCTB14 is one of 39 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Consolidative Therapy
SSun Yat-sen University
Phase 3
SCTB14
SSinocelltech Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCTB14. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSinocelltech Ltd.